The Pivotal Role of Tumor Stem Cells in Glioblastoma
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Stem Cells".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 5401
Special Issue Editors
Interests: inflammation; glioma; cancer stem cells; tumor biology; cyclooxygenase-2; nitric oxide synthase 2
Special Issues, Collections and Topics in MDPI journals
Interests: dicarbonyl stress; oxidative stress; mitochondrial metabolism
Special Issue Information
Dear Colleagues,
We are delighted to announce the launch of a Special Issue of Cells on all aspects related to the theme of “The Pivotal Role of Tumor Stem Cells in Glioblastoma”. We invite you to contribute original research articles or reviews to share your cutting-edge research, insights, and innovation on new mechanistic, functional, cellular, biochemical, or general evidence of cancer stem cells in glioblastoma.
Glioblastoma is one of the most complex, fast-growing, aggressive, and treatment-resistant cancers with an extremely poor prognosis. The latest therapeutic approaches are rarely effective due to the presence of tumor stem cells (TSC) that play a crucial role in resistance and recurrence.
TSCs can also strongly affect the tumor microenvironment, influencing all neighboring resident cell fate by genetic reprogramming and inducing some key stemness features. The precise molecular mechanisms underlying the intricate scenario of TSC are not yet fully understood. A deeper understanding of the TSCs' molecular and biological features could certainly allow us to define new, targeted, and more effective therapeutic approaches to overcome cancer resistance to improve survival rate and treatment response.
We look forward to your contributions.
Dr. Paola Palumbo
Dr. Silvano J. Santini
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioblastoma stem cells
- resistance
- cancer therapy
- signaling pathways
- tumor microenvironment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Microglia-Derived Brain Macrophages Associate with Glioblastoma Stem Cells: A Potential Mechanism for Tumour Progression Revealed by AI-Assisted Analysis
Authors: YUQI ZHENG1, HANEYA FUSE2, ISLAM ALZOUBI3 and MANUEL B. GRAEBER1,4*
Affiliation: 1. Ken Parker Brain Tumour Research Laboratories, Brain and Mind Centre, Faculty of Medicine and Health, University of Sydney, NSW 2050, Australia
2. School of Medicine, Sydney Campus, University of Notre Dame, 160 Oxford Street, Darlinghurst, Sydney, NSW 2010, Australia
3. School of Computer Science, The University of Sydney, J12/1 Cleveland St, Darlington, Sydney, NSW 2008, Australia
4. University of Sydney Association of Professors (USAP), University of Sydney, NSW 2006, Australia (current)
*Address for correspondence: [email protected]
Abstract: Malignant gliomas are highly aggressive brain tumours, and understanding the mechanisms underlying their progression is crucial for developing more effective treatments. Recent studies have highlighted the role of microglia and brain macrophages in glioblastoma development, but the specific interactions between these immune cells and glioblastoma stem cells (GSCs) remain unclear. To address this question, we have utilised AI-assisted cell recognition to investigate the spatial relationship between GSCs expressing high levels of CD276 and microglia- and bone marrow-derived brain macrophages, respectively. Using PathoFusion, our previously developed open-source AI framework, we were able to map immunohistochemical data at the single-cell level within whole-slide images. This approach enabled us to selectively identify Iba1+ and CD163+ macrophages as well as CD276+ GSCs with high specificity. Our analysis suggests a closer association of Iba1+ macrophages with GSCs than between CD163+ macrophages and GSCs in glioblastoma tissue samples. Our findings provide novel insights into the spatial context of tumour immunity in glioblastoma and point to microglia-GSC interactions as a potential mechanism for tumour progression during early diffuse tissue infiltration. These results have implications for our understanding of glioblastoma biology and provide a starting point for a systematic analysis of the different microglia activation phenotypes during glioma development which may lead to new therapeutic strategies targeting the early stages of the immune microenvironment of glioblastoma.